Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

CBD may reduce Alzheimer’s pathology and improve cognition

Staff Writer
Staff Writer 3 years ago
Updated 2021/05/12 at 6:18 PM
Share
SHARE

While the effects of CBD on mental health remain the subject of vigorous research, more studies are indicating its potential as a therapeutic approach for some brain conditions.

In the Medical College of Georgia at Augusta University, researchers concluded that CBD may decrease Alzheimer’s pathology, improving cognition among adults.

The study appeared in the Journal of Alzheimer’s Disease.

“The proteins TREM2 and IL-33 are important to the ability of the brain’s immune cells to literally consume dead cells and other debris like the beta-amyloid plaque that piles up in patients’ brains, and levels of both are decreased in Alzheimer’s,” the authors of the study stated in a press release.

In the study, researchers revealed that CBD may in fact stabilize levels of a protein known as IL-33, which plays a role in detecting beta-amyloid accumulation.

“They found CBD appears to normalize levels of IL-33, a protein whose highest expression in humans is normally in the brain, where it helps sound the alarm that there is an invader like the beta-amyloid accumulation. There is emerging evidence of its role as a regulatory protein as well, whose function of either turning up or down the immune response depends on the environment. In Alzheimer’s, that includes turning down inflammation and trying to restore balance to the immune system,” the news release reads.

“BD should be at least equally effective in the more common, nonfamilial type Alzheimer’s, which likely have more targets for CBD. They already are looking at its potential in a model of this more common type and moving forward to establish a clinical trial.”

Photo: labroots

You Might Also Like

Study boasts MDMA-assisted therapy for PTSD patients

Study claims the more people think God, the more likely they trust AI decision-making

How the brain is organized is revealed by the largest genetic study of brain structure to date

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

New study reveals positive results from postpartum depression treatment Zuranolone

TAGGED: CBD, IL-33, Alzheimer's disease, cognition
Staff Writer March 9, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article How smoking cessation drastically improves mental health conditions
Next Article Researchers find a new link between amyloid pathology and age-related sight loss

Recommended

Clinical

Study boasts MDMA-assisted therapy for PTSD patients

1 Min Read
Cyber

Study claims the more people think God, the more likely they trust AI decision-making

2 Min Read
Clinical

How the brain is organized is revealed by the largest genetic study of brain structure to date

2 Min Read
Clinical

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

3 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?